<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35024335</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2213-4220</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Integrative medicine research</Title>
          <ISOAbbreviation>Integr Med Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Chinese herbal medicine for myasthenia gravis: A systematic review and meta-analysis of randomized clinical trials.</ArticleTitle>
        <Pagination>
          <StartPage>100806</StartPage>
          <MedlinePgn>100806</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">100806</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.imr.2021.100806</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Myasthenia Gravis (MG) is a disorder of neuromuscular transmission bringing mild ocular weakness to severe generalized muscle weakness and disability. The conventional treatments have long-term side effects, and Chinese herbal medicines (CHM) have shown possible effect and safety for MG patients, but the existing evidence was not robust enough and the results were out of date.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Searching for randomized controlled trials (RCTs) was conducted in 7 databases and clinical trial registries until July 2021. The ROB 2 tool was used to assess the study quality and GRADE was used to assess the quality of whole evidence. Meta-analyses were conducted and the results were presented as risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Nineteen RCTs (1283 participants) testing 13 kinds of CHM with adequate randomization were included and six RCTs investigating Compound Huangqi were included in the meta-analyses. In addition to conventional treatment, nine CHMs reduced symptom scores of MG. Compound Huangqi plus conventional treatment (pyridostigmine bromide or prednisone or both) reduced the symptom scores compared with conventional treatment (MD = -3.56, 95%CI -4.86 to -2.26). Less adverse events happened in the CHM groups (3/247 in the CHM groups, 52/245 in the control groups, RR = 0.13, 95%CI 0.06 to 0.30, 9 RCTs, a total of 492 participants). The effect on quality of life was inconsistent.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nine CHMs could probably bring benefit for MG symptom improvement. Moderate to low certainty of evidence supported Compound Huangqi added-on conventional treatment probably bring extra benefit of improving MG symptoms. Adding CHMs could be safer than giving only conventional treatment.</AbstractText>
          <AbstractText Label="STUDY REGISTRATION" NlmCategory="BACKGROUND">The protocol was registered in PROSPERO (ID: 32718).</AbstractText>
          <CopyrightInformation>© 2021 Korea Institute of Oriental Medicine. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Si-Jia</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Rui-Ting</ForeName>
            <Initials>RT</Initials>
            <AffiliationInfo>
              <Affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Ze-Yu</ForeName>
            <Initials>ZY</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Ruo-Xiang</ForeName>
            <Initials>RX</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Chang-Hao</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>You-You</ForeName>
            <Initials>YY</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fang</LastName>
            <ForeName>Min</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Mei</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Jian-Ping</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R24 AT001293</GrantID>
            <Acronym>AT</Acronym>
            <Agency>NCCIH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Integr Med Res</MedlineTA>
        <NlmUniqueID>101612707</NlmUniqueID>
        <ISSNLinking>2213-4220</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chinese herbal medicine</Keyword>
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Randomized clinical trials</Keyword>
        <Keyword MajorTopicYN="N">Symptom score</Keyword>
        <Keyword MajorTopicYN="N">Systematic review</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>12</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35024335</ArticleId>
        <ArticleId IdType="pmc">PMC8733270</ArticleId>
        <ArticleId IdType="doi">10.1016/j.imr.2021.100806</ArticleId>
        <ArticleId IdType="pii">S2213-4220(21)00093-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gilhus N.E., Verschuuren J.J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14:1023–1036. doi: 10.1016/S1474-4422(15)00145-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(15)00145-3</ArticleId>
            <ArticleId IdType="pubmed">26376969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanders D.B., Wolfe G.I., Benatar M., et al.  International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87:419–425. doi: 10.1212/WNL.0000000000002790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000002790</ArticleId>
            <ArticleId IdType="pmc">PMC4977114</ArticleId>
            <ArticleId IdType="pubmed">27358333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boldingh M.I., Dekker L., Maniaol A.H., et al.  An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes. 2015;13:115. doi: 10.1186/s12955-015-0298-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12955-015-0298-1</ArticleId>
            <ArticleId IdType="pmc">PMC4522107</ArticleId>
            <ArticleId IdType="pubmed">26232146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Narayanaswami P., Sanders D.B., Wolfe G., et al.  International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114–122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. PMID: 33144515; PMCID: PMC7884987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000011124</ArticleId>
            <ArticleId IdType="pmc">PMC7884987</ArticleId>
            <ArticleId IdType="pubmed">33144515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon D., Barnett C., Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538. doi: 10.3389/fneur.2020.00538. PMID: 32714266; PMCID: PMC7344308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00538</ArticleId>
            <ArticleId IdType="pmc">PMC7344308</ArticleId>
            <ArticleId IdType="pubmed">32714266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S., Xu M.B., Zhou X.L., Rong P.Q., Jin T.Y., Zheng G.Q. Chinese herbal medicine for myasthenia gravis: a systematic review and meta-analysis. Front Pharmacol. 2018;9:969. doi: 10.3389/fphar.2018.00969. PMID: 30214409; PMCID: PMC6125412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.00969</ArticleId>
            <ArticleId IdType="pmc">PMC6125412</ArticleId>
            <ArticleId IdType="pubmed">30214409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sterne J.A.C., Savović J., Page M.J., et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898. https://www.riskofbias.info/welcome PMID: 31462531. Can be reached at.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId>
            <ArticleId IdType="pubmed">31462531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schünemann H.J., Higgins J.P.T., Vist G.E., et al.   In: Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021) Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane; 2021. Chapter 14: completing ‘Summary of findings’ tables and grading the certainty of the evidence. Available from.</Citation>
        </Reference>
        <Reference>
          <Citation>Li D.Y. Neuroimmunology group, Chinese medical association neurology branch; neuroimmunology branch of Chinese society of immunology Chinese guidelines for the diagnosis and treatment of myasthenia gravis 2015. Chinese J Neurol. 2015;48(11):934–940. doi: 10.3760/cma.j.issn.1006-7876.2015.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3760/cma.j.issn.1006-7876.2015.11.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedlack R.S., Simel D.L., Bosworth H., Samsa G., Tucker-Lipscomb B., Sanders D.B. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology. 2005;64(11):1968–1970. doi: 10.1212/01.WNL.0000163988.28892.79. https://myasthenia.org/Professionals/Resources-for-Professionals PMID: 15955957. can be reached at.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000163988.28892.79</ArticleId>
            <ArticleId IdType="pubmed">15955957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X.Y., Xiu X.H., Sun H., Han X., Zhang H., Guo H. A clinical absolute and relative score system for myasthenia gravis. Chinese J Neurol. 1997;02:24–27.</Citation>
        </Reference>
        <Reference>
          <Citation>Deeks J.J., Higgins J.P.T., Altman D.G., et al.   In: Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021) Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane; 2021. Chapter 10: analysing data and undertaking meta-analyses. Available from.</Citation>
        </Reference>
        <Reference>
          <Citation>Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi: 10.1136/bmj.327.7414.557. PMID: 12958120; PMCID: PMC192859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId>
            <ArticleId IdType="pmc">PMC192859</ArticleId>
            <ArticleId IdType="pubmed">12958120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page M.J., Higgins J.P.T., Sterne J.A.C, et al.   In: Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021) Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane; 2021. Chapter 13: assessing risk of bias due to missing results in a synthesis. Available from.</Citation>
        </Reference>
        <Reference>
          <Citation>Xu Xian-hao.  Beijing Medical University, China Union Medical University, Associated Press; Beijing: 2001. Neuroimmunology; pp. 100–155.</Citation>
        </Reference>
        <Reference>
          <Citation>Busch C., Machens A., Pichlmeier U., et al.  Long-term outcome and quality of life after thymectomy for myasthenia gravis. Ann. Surg. 1996;224(2):225–232. doi: 10.1097/00000658-199608000-00017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000658-199608000-00017</ArticleId>
            <ArticleId IdType="pmc">PMC1235346</ArticleId>
            <ArticleId IdType="pubmed">8757388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao B.  Liaoning University of Traditional Chinese Medicine; 2016. Observation of clinical curative effect of Engelhardtia compound granules in treating myasthenia gravis.</Citation>
        </Reference>
        <Reference>
          <Citation>Bao B., Zhang J.S., Qiao W.J. Clinical observation on treatment of myasthenia gravis with engelhardtia compound granules. J Guangxi Univers Chinese Med. 2016;19(01):13–15.</Citation>
        </Reference>
        <Reference>
          <Citation>Chen M.L.  Fujian University of Traditional Chinese Medicine; 2020. The clinical efficacy observation of qilian prescription in the treatment of ocular myasthenia gravis with spleen-deficiency and dampness-heat type.</Citation>
        </Reference>
        <Reference>
          <Citation>Guo Y., Zhang L.Y. Clinical observation of self-made Yiqijianpi decoction combined with bropistigmine in the treatment of patients with myasthenia gravis. China's Naturopathy. 2020;28(03):57–60.</Citation>
        </Reference>
        <Reference>
          <Citation>He T.  Chengdu University of Traditional Chinese Medicine; 2016. Clinical Observation On the Treatment of Myasthenia Gravis With Reinforcing Spleen and Nourishing Kidney.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang C., Liu P., Zhang J., et al.  Clinical study of effects of Jian Ji Ning, a Chinese herbal medicine compound preparation, in treating patients with myasthenia gravis via the regulation of differential MicroRNAs expression in serum. Evid Based Complement Alternat Med. 2014;2014 doi: 10.1155/2014/518942. Epub 2014 Jan 5. PMID: 24734107; PMCID: PMC3956408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/518942</ArticleId>
            <ArticleId IdType="pmc">PMC3956408</ArticleId>
            <ArticleId IdType="pubmed">24734107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju G.S.  Chengdu University of Traditional Chinese Medicine; 2003. Tanwei capsule and prednisone in the treatment of myasthenia gravis: a randomized controlled trial.</Citation>
        </Reference>
        <Reference>
          <Citation>Lai J.  Guiyang University of Traditional Chinese Medicine; 2013. Study on the immunoregulatory effect of the Bupiqiangli decoction on myasthenia gravis with spleen and kidney deficiency.</Citation>
        </Reference>
        <Reference>
          <Citation>Li D.F.  Shandong University of Traditional Chinese Medicine; 2012. Clinical observation of Qi and dampness treatment of myasthenia gravis and research of the immune regulation mechanism.</Citation>
        </Reference>
        <Reference>
          <Citation>Li Z.Q.  Liaoning University of Traditional Chinese Medicine; 2019. The clinical efficacy of compound Huangqi decoction in the treatment of Type I and II myasthenia gravis patients after thymoma operation.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu X.Y., Fan L. Effects of Buzhong Yiqi decoction on Treg cells, lymphocyte subsets and therapeutic effect in elderly patients with myasthenia gravis. World J Tradition Chinese Med. 2020;15(21):3336–3339.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma Y.  Henan University of Traditional Chinese Medicine; 2016. Clinical observation of the reinforcing kidney and spleen theory for treating myasthenia gravis.</Citation>
        </Reference>
        <Reference>
          <Citation>Niu G.H.  Liaoning University of Traditional Chinese Medicine; 2009. The complex recipe of astragalus membranaceus's clinical effect in treating myasthenia graves.</Citation>
        </Reference>
        <Reference>
          <Citation>Ou Z.S.  Guangzhou University of Traditional Chinese Medicine; 2005. Clinical study on Qiangji Jianli Yin in treating myasthenia gravis.</Citation>
        </Reference>
        <Reference>
          <Citation>Sheng W.D.  Henan University of Traditional Chinese Medicine; 2018. Nerve electrophysiological effect of the adjusted prescription of Buzhong Yiqi decoction on myasthenia gravis (flaccidity syndrome) two spleen and kidney deficiency.</Citation>
        </Reference>
        <Reference>
          <Citation>Yan J.  Henan University of Traditional Chinese Medicine; 2016. The effect of the flavored Buzhongyiqi decoction on clinical curative and humoral immune factors in patients with myasthenia gravis.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu Y.Y.  Liaoning University of Traditional Chinese Medicine; 2018. The clinical curative effect of compound Huangqi decoction combined with pyridostigmine for juvenile oculomotor myasthenia gravis.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu Y.Y., Qiao W.J. Observation of effect of modified compound Huangqi decoction on myasthenia gravis of spleen and kidney deficiency. Shanxi J Tradition Chinese Med. 2017;33(10):20–22. +25.</Citation>
        </Reference>
        <Reference>
          <Citation>Yuan Y.K.  Henan University of Traditional Chinese Medicine; 2017. The clinical observation of Qi-supplementing kidney-tonifying recipe on myasthenia gravis.</Citation>
        </Reference>
        <Reference>
          <Citation>Guo Z., Lou Y., Kong M., Luo Q., Liu Z., Wu J. A systematic review of phytochemistry, pharmacology and pharmacokinetics on astragali radix: implications for astragali radix as a personalized medicine. Int J Mol Sci. 2019;20(6):1463. doi: 10.3390/ijms20061463. PMID: 30909474; PMCID: PMC6470777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20061463</ArticleId>
            <ArticleId IdType="pmc">PMC6470777</ArticleId>
            <ArticleId IdType="pubmed">30909474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J.E., Kim B.B., Ko Y., Jeong S.H., Park J.B. Effects of Cimicifugae Rhizoma on the osteogenic and adipogenic differentiation of stem cells. Exp Ther Med. 2017;13(2):443–448. doi: 10.3892/etm.2016.4010. Epub 2016 Dec 29. PMID: 28352313; PMCID: PMC5348703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/etm.2016.4010</ArticleId>
            <ArticleId IdType="pmc">PMC5348703</ArticleId>
            <ArticleId IdType="pubmed">28352313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang R.F., Ge W.J., Wei Z., et al.  [Effect of Saposhnikoviae Radix on pharmacokinetics and tissue distributions of active components in Tongxie Yaofang in rats] Zhongguo Zhong Yao Za Zhi. 2017;42(19):3802–3808. doi: 10.19540/j.cnki.cjcmm.20170901.005. ChinesePMID: 29235298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20170901.005</ArticleId>
            <ArticleId IdType="pubmed">29235298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruqiao L., Yueli C., Xuelan Z., et al.  Rhizoma Atractylodis macrocephalae: a review of photochemistry, pharmacokinetics and pharmacology. Pharmazie. 2020;75(2):42–55. doi: 10.1691/ph.2020.9738. PMID: 32213234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1691/ph.2020.9738</ArticleId>
            <ArticleId IdType="pubmed">32213234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F., Dong X., Yin X., Wang W., You L., Ni J. Radix Bupleuri: a review of traditional uses, botany, phytochemistry, pharmacology, and toxicology. Biomed Res Int. 2017;2017 doi: 10.1155/2017/7597596. Epub 2017 May 16. PMID: 28593176; PMCID: PMC5448051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2017/7597596</ArticleId>
            <ArticleId IdType="pmc">PMC5448051</ArticleId>
            <ArticleId IdType="pubmed">28593176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma T.T., Feng X.Z., Wang X.Y. [Effects and mechanism of Angelicae Sinensis radix on Th1/Th2 and Th17/Treg in mice with asthma and Yin deficiency syndrome] Zhongguo Zhong Yao Za Zhi. 2017;42(4):758–762. doi: 10.19540/j.cnki.cjcmm.20170121.037. ChinesePMID: 28959849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.19540/j.cnki.cjcmm.20170121.037</ArticleId>
            <ArticleId IdType="pubmed">28959849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu W., Saiki S., Myojin T., et al.  Lycii fructus extract ameliorates hydrogen peroxide-induced cytotoxicity through indirect antioxidant action. Biosci Biotechnol Biochem. 2018;82(10):1812–1820. doi: 10.1080/09168451.2018.1487274. Epub 2018 Jun 18. PMID: 29912670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09168451.2018.1487274</ArticleId>
            <ArticleId IdType="pubmed">29912670</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
